Seeking a way to stimulate antitumor responses via the immune system, Steven Fiering, PhD, of Norris Cotton Cancer Center at Dartmouth, has identified the precise temperature that results in a distinct body-wide antitumor immune response that resists metastatic disease.
Tekmira Pharmaceuticals Corporation, an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that the partial clinical hold on the company's Investigational New Drug application (IND) for TKM-Ebola has been modified to permit repeat dosing of healthy volunteers at a dose of 0.24 mg/kg/day. The IND remains on partial clinical hold with regard to doses above 0.24 mg/kg/day in healthy volunteers.
Dicerna Pharmaceuticals, Inc., a leader in the development of RNAi therapeutics, today announced promising new in vivo data for CTNNB1 DsiRNA in multiple patient-derived xenograft (PDX) and other models of diverse tumor types. CTNNB1 DsiRNA is an extended Dicer substrate short interfering RNA (DsiRNA-EX) therapeutic targeting â-catenin delivered using Dicerna’s proprietary next generation EnCore™ lipid nanoparticle (LNP) technology.
Teri Odom of Northwestern University will present a seminar at 3:30 p.m. Monday, April 13, in CHEM 144 on gold nanostar probes for imaging and therapeutics.
A team of scientists from the Institute for Biotechnology and Biomedicine at the UAB has produced an alternative to the use of viruses in gene therapy. The researchers synthesised nanoparticles which act as artificial viruses, capable of surrounding DNA fragments and releasing them as therapeutic agents, with no biological risk, into the interior of the cells.
The chemist Dr. Pavel Levkin of Karlsruhe Institute of Technology (KIT) is granted the 2015 Heinz Maier-Leibnitz Prize by the German Research Foundation (DFG). The prize is considered the highest distinction for young researchers in Germany. Scientific work of Pavel Levkin focuses on the investigation of cell-surface interactions, the development of biofunctional materials and super-water-repellent surfaces as well as on nanoparticles for specific medicine and gene transport. A major scientific success of Levkin was the synthesis of lipid-like molecules for gene modification of cells.
Cancer cells often break free from their original locations and circulate through the bloodstream, allowing them to form new tumors elsewhere in the body.
It is well known that neurological diseases and injuries pose some of the greatest challenges in modern medicine, with few if any options for effectively treating such diagnoses, but recent work suggests a unique approach for reconstructing damaged neural tissue.
Particle Sciences, a leading drug delivery CDMO, has received a Notice of Allowance for composition and use of the technology incorporated into its SATx™ platform.
A group of MIPT researchers together with their colleagues from Moscow, Nizhny Novgorod, Australia and the Netherlands have carried out the first systematic study analyzing the safety of so-called upconversion nanoparticles that may be used to treat skin cancer and other skin diseases. This study is one of the most important steps on the path to new, safe and effective methods to diagnose and treat cancer.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.